Business
Investor Presentation via Investor Meet Company
Cambridge Cognition Holdings PLC announced that Rob Baker, Group Chief Operating Officer, and Ronald Openshaw, Chief Financial Officer, will deliver a live presentation regarding the Interim Results via Investor Meet Company on September 3, 2025, at 11:00 BST. The presentation is accessible to both current and prospective shareholders. Questions can be submitted through the Investor Meet Company dashboard before September 2, 2025, at 09:00 BST, or during the live presentation. Interested parties can register for free on the Investor Meet Company platform to attend and follow Cambridge Cognition Holdings PLC. Disclaimer*
About this update from Cambridge Cognition Holdings Plc
01 September 2025 Cambridge Cognition Holdings plc ("Cambridge Cognition", the "Company" or the "Group") Investor Presentation via Investor Meet Company Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce that Rob Baker (Group Chief Operating Officer and Senior Executive Director) and Ronald Openshaw (Chief Financial Officer and Head of Corporate Development) will provide a live presentation relating to the Interim Results via Investor Meet Company on 03 September 2025, 11:00 BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 02 September 2025, 09:00 BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Cambridge Cognition Holdings plc via: https://www.investormeetcompany.com/cambridge-cognition-holdings-plc/register-investor Investors who already follow Cambridge Cognition Holdings plc on the Investor Meet Company platform will automatically be invited. Enquiries: Cambridge Cognition Holdings plc Rob Baker, Group Chief Operating Officer and Senior Executive Director Tel: 012 2381 0700 [email protected] Panmure Liberum Limited (NOMAD and Joint Broker) Will Goode / Freddy Crossley / Mark Rogers Rupert Dearden Tel: 020 7886 2968 (Corporate Finance) (Corporate Broking) Dowgate Capital Limited (Joint Broker) David Poutney / Amber Higgs Tel: 020 3903 7715 Notes to Editors About Cambridge Cognition Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment. Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors: · Clinical Studies for new pharmaceuticals; · Academic Research for scientists to understand CNS disorders; · Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and, · Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health. For further information, visit: www.cambridgecognition.com END
View stock analysis, news, and events for Cambridge Cognition Holdings Plc